Does lurbinectedin cause anemia?
Yes, lurbinectedin (branded as Zepzelca) commonly causes anemia. In clinical trials for small cell lung cancer, anemia occurred in 72% of patients, with 22% experiencing severe (Grade 3/4) cases. This is due to the drug's mechanism as a selective inhibitor of oncogenic transcription, which disrupts rapidly dividing cancer cells but also affects bone marrow function, reducing red blood cell production.[1][2]
How severe is anemia from lurbinectedin?
Most cases are mild to moderate and managed with transfusions or supportive care, but severe anemia can lead to fatigue, shortness of breath, or hospitalization. In the pivotal IMphase trial, 20% of patients needed transfusions. Monitoring complete blood counts is standard before each cycle.[1][3]
What other blood-related side effects occur?
Lurbinectedin frequently causes:
- Neutropenia (65%, with 45% severe).
- Thrombocytopenia (45%, with 15% severe).
These myelosuppressive effects stem from its impact on hematopoietic cells. Dose delays or reductions happen in about 40% of patients due to cytopenias.[1][2]
How is lurbinectedin-induced anemia managed?
- Hold treatment if hemoglobin drops below 8 g/dL.
- Transfuse packed red blood cells as needed.
- Use erythropoiesis-stimulating agents cautiously due to tumor progression risks.
- Prophylactic growth factors like G-CSF are recommended for neutropenia but not routinely for anemia.[3][4]
Who is at higher risk for anemia?
Patients with prior chemotherapy, poor performance status, or low baseline hemoglobin face elevated risks. Elderly patients or those with liver impairment may need closer monitoring, as lurbinectedin clearance slows.[2][4]
How does lurbinectedin compare to other SCLC treatments for anemia?
Compared to topotecan (standard second-line), lurbinectedin shows similar anemia rates (around 70%) but better overall response (35% vs. 15%) and survival. Irinotecan combos have lower anemia incidence but more diarrhea.[1][5]
Sources
[1]: FDA Label for Zepzelca
[2]: IMphase Trial (Trigo et al., Lancet Oncology 2020)
[3]: NCCN Guidelines for SCLC
[4]: Drugs.com - Lurbinectedin Side Effects
[5]: ASCO Post - Lurbinectedin Review